$10.92
+0.75
(+7.37%)▲
Revenue is up for the last 2 quarters, 6.78M → 12.68M (in $), with an average increase of 46.5% per quarter
Netprofit is up for the last 2 quarters, -46.71M → -40.73M (in $), with an average increase of 14.7% per quarter
In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 36.3%
7.14%
Downside
Day's Volatility :8.32%
Upside
1.27%
23.63%
Downside
52 Weeks Volatility :58.11%
Upside
45.15%
Period | NURIX THERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 21.87% | 0.9% | -8.3% |
6 Months | -11.79% | -6.8% | -6.5% |
1 Year | 3.12% | 0.4% | -6.1% |
3 Years | -42.56% | 28.3% | 21.8% |
Market Capitalization | 482.5M |
Book Value | $5.78 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.53 |
Wall Street Target Price | 28.27 |
Profit Margin | 0.0% |
Operating Margin TTM | -441.52% |
Return On Assets TTM | -28.48% |
Return On Equity TTM | -61.58% |
Revenue TTM | 41.7M |
Revenue Per Share TTM | 0.82 |
Quarterly Revenue Growth YOY | 31.8% |
Gross Profit TTM | -145.9M |
EBITDA | -179.2M |
Diluted Eps TTM | -3.53 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.04 |
EPS Estimate Next Year | -3.39 |
EPS Estimate Current Quarter | -0.87 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 158.88%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 37.4M | - |
Net Income | -9.4M | - |
Net Profit Margin | -25.18% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.1M | ↓ 16.91% |
Net Income | -21.7M | ↑ 130.15% |
Net Profit Margin | -69.74% | ↓ 44.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 17.8M | ↓ 42.73% |
Net Income | -43.2M | ↑ 99.28% |
Net Profit Margin | -242.66% | ↓ 172.92% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 29.8M | ↑ 66.95% |
Net Income | -117.2M | ↑ 171.02% |
Net Profit Margin | -393.93% | ↓ 151.27% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 38.6M | ↑ 29.84% |
Net Income | -180.4M | ↑ 53.9% |
Net Profit Margin | -466.93% | ↓ 73.0% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↓ 27.86% |
Net Income | -37.7M | ↑ 30.75% |
Net Profit Margin | -509.76% | ↓ 228.5% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 9.6M | ↑ 30.08% |
Net Income | -42.5M | ↑ 12.81% |
Net Profit Margin | -442.09% | ↑ 67.67% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.4M | ↑ 18.82% |
Net Income | -45.4M | ↑ 6.74% |
Net Profit Margin | -397.14% | ↑ 44.95% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.8M | ↓ 5.61% |
Net Income | -45.7M | ↑ 0.68% |
Net Profit Margin | -423.58% | ↓ 26.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.8M | ↓ 37.14% |
Net Income | -46.7M | ↑ 2.21% |
Net Profit Margin | -688.74% | ↓ 265.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.7M | ↑ 87.01% |
Net Income | -40.7M | ↓ 12.81% |
Net Profit Margin | -321.11% | ↑ 367.63% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 45.4M | - |
Total Liabilities | 82.2M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 44.0M | ↓ 2.97% |
Total Liabilities | 101.8M | ↑ 23.73% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 396.3M | ↑ 799.8% |
Total Liabilities | 106.1M | ↑ 4.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 476.8M | ↑ 20.29% |
Total Liabilities | 134.5M | ↑ 26.77% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 416.8M | ↓ 12.59% |
Total Liabilities | 113.1M | ↓ 15.92% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 476.8M | ↓ 3.31% |
Total Liabilities | 134.5M | ↑ 14.1% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 437.7M | ↓ 8.19% |
Total Liabilities | 131.8M | ↓ 1.98% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 394.3M | ↓ 9.92% |
Total Liabilities | 127.6M | ↓ 3.21% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 459.3M | ↑ 16.49% |
Total Liabilities | 116.8M | ↓ 8.45% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 416.8M | ↓ 9.27% |
Total Liabilities | 113.1M | ↓ 3.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 370.2M | ↓ 11.18% |
Total Liabilities | 96.1M | ↓ 15.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.7M | - |
Investing Cash Flow | 40.0M | - |
Financing Cash Flow | 529.0K | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 601.0K | ↓ 101.9% |
Investing Cash Flow | 8.5M | ↓ 78.75% |
Financing Cash Flow | 126.0K | ↓ 76.18% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.0K | ↓ 113.31% |
Investing Cash Flow | -254.4M | ↓ 3093.69% |
Financing Cash Flow | 339.0M | ↑ 268966.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -84.4M | ↑ 105356.25% |
Investing Cash Flow | -108.3M | ↓ 57.45% |
Financing Cash Flow | 153.9M | ↓ 54.61% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -159.8M | ↑ 89.42% |
Investing Cash Flow | 27.2M | ↓ 125.12% |
Financing Cash Flow | 117.2M | ↓ 23.84% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.9M | ↑ 3.13% |
Investing Cash Flow | -36.5M | ↑ 198.61% |
Financing Cash Flow | 500.0K | ↓ 67.78% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -42.6M | ↑ 37.91% |
Investing Cash Flow | 40.0M | ↓ 209.6% |
Financing Cash Flow | 1.5M | ↑ 197.6% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -32.9M | ↓ 22.79% |
Investing Cash Flow | -4.8M | ↓ 111.9% |
Financing Cash Flow | 432.0K | ↓ 70.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -88.9M | ↑ 170.21% |
Investing Cash Flow | -63.1M | ↑ 1223.74% |
Financing Cash Flow | 116.9M | ↑ 26959.03% |
Sell
Neutral
Buy
NURIX THERAPEUTICS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() NURIX THERAPEUTICS INC | 15.68% | -11.79% | 3.12% | -42.56% | -42.56% |
![]() Moderna, Inc. | -2.84% | -25.82% | -6.78% | 115.4% | 601.67% |
![]() Regeneron Pharmaceuticals, Inc. | -1.85% | -2.05% | 21.5% | 23.63% | 137.1% |
![]() Seagen, Inc. | -1.57% | 61.18% | 37.09% | 29.88% | 217.64% |
![]() Vertex Pharmaceuticals Incorporated | -3.7% | 5.09% | 24.54% | 22.34% | 123.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() NURIX THERAPEUTICS INC | NA | NA | NA | -3.04 | -0.62 | -0.28 | 0.0 | 5.78 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() NURIX THERAPEUTICS INC | Buy | $482.5M | -42.56% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 601.67% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 137.1% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 217.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 123.04% | 26.18 | 35.4% |
BlackRock Inc
Baker Bros Advisors LP
Wasatch Advisors Inc.
Deep Track Capital, LP
Redmile Group, LLC
Vanguard Group Inc
NURIX THERAPEUTICS INC’s price-to-earnings ratio stands at None
Read MoreNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
Organization | NURIX THERAPEUTICS INC |
Employees | 297 |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Industry | Health Technology |
ProShares Bitcoin Strategy ETF
$15.29
+1.8%
Invesco Dynamic Software ETF
$105.19
+0.54%
ARROWROOT ACQUISITION CORP-A
$10.38
-0.09%
SimilarWeb Ltd
$6.74
+3.37%
Rimini Street Inc
$4.29
+1.66%
SENTI BIOSCIENCES INC
$0.93
+5.87%
WISDOMTREE US EFFICIENT CORE
$36.20
+0.84%
XOMA CORP
$17.97
+5.64%
Madison Square Garden Entertainment Corporation
$40.09
+9.48%